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Background: Hereditary hemochromatosis (HH) is a primary iron overload (IO) condition.
Absolute telomere length (ATL) is a marker of cellular aging and DNA damage associated
with chronic diseases and mortality.
Aim: To evaluate the relationship between ATL and IO in patients with HH.
Methods: Cross-sectional study including 25 patients with HH: 8 with IO and 17 without IO
(ferritin < 300 ng/ml) and 25 healthy controls. Inclusion criteria were: age > 18 years, male
sex and HH diagnosis. Patients with diabetes or other endocrine and autoimmune diseases
were excluded. ATL was measured by real-time PCR.
Results: HH patients with IO were older (P<0.001) and showed higher ferritin concentration
(P<0.001). Patients with HH, disregarding the iron status, showed higher glucose and body
mass index (BMI) than controls (both P<0.01). ATL was shorter in patients with IO than
controls [with IO: 8 (6–14), without IO: 13 (9–20), and controls: 19 (15–25) kilobase pairs,
P<0.01]; with a linear trend within groups (P for trend <0.01). Differences in ATL remained
statistically significant after adjusting by age, BMI and glucose (P<0.05).
Discussion: Patients with IO featured shorter ATL while patients without IO showed only
mild alterations vs. controls. Screening for IO is encouraged to prevent iron-associated cel-
lular damage and early telomere attrition.
Introduction
Hereditary hemochromatosis (HH) is a primary condition, which might lead to iron overload (IO) de-
pending on host and ambient factors. Two main types of HH have been described: (1) the recessive type
which involves genes that are related to the activation of hepcidin such as the human homeostatic iron
regulator (HFE), hemojuvelin (HJV), and hepcidin (HAMP) genes; and (2) the dominant type which in-
volves the hepcidin receptor ferroportin (FPN). Among these, the main gene associated with HH is HFE,
located in the short arm of chromosome 6 (6p). The HFE gene encodes a protein that is located on the sur-
face of cells, primarily liver, intestinal and immune cells. This protein interacts with other proteins on the
cell surface to detect the amount of iron in the body. When the HFE protein is bound to the transferrin (Tf)
receptor (TfR) 1, the receptor cannot bind to Tf preventing the entrance of iron to liver cells. Furthermore,
HFE protein regulates the production of hepcidin. Hepcidin is produced by the liver, and it regulates iron
absorption from the diet and its release from storage sites in the body. When the HFE protein is not bound
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to TfR 1, it binds to a group of other proteins that include hepcidin triggering the production of hepcidin. Therefore,
binding of HFE protein to TfR 1 represses hepcidin expression. Consequently, current models of iron metabolism
regulation propose that highly iron-saturated Tf would release HFE protein from TfR1 increasing iron uptake by cells
and hepcidin up-regulation [1,2].
Even if iron is essential for cells, it may also be involved in the generation of reactive oxygen species leading to
cellular damage [3–7]. In patients with IO, the hepatocytes, cardiomyocytes and cells from endocrine organs, may
be affected [8]. Clinical manifestations of overt IO in patients with HH include altered liver enzymes, hepatocellular
carcinoma, osteoarthritis, glucose intolerance and diabetes, sexual hormone disorder, cardiac dysfunction and hy-
perpigmentation, among others [8]. In fact, IO would decrease insulin secretion and increase β-cell apoptosis via
iron-induced oxidative stress [9]. Likewise, oxidative stress would be responsible for the liver damage found in IO
patients [10,11]. Moreover, IO would be associated with increased atherosclerotic plaque formation and risk of my-
ocardial infarction [12,13]. On the contrary, iron depletion, the most common and effective treatment for IO patients,
would decrease low-density lipoprotein (LDL) oxidation and increase high-density lipoprotein cholesterol (HDL-C)
levels [13]. Consistently, prior studies carried out by our group showed that HDL from IO patients present both
quantitative and qualitative alterations associated with higher risk of cardiovascular disease [14,15].
Absolute telomere length (ATL) is related to aging and cellular damage. As a biomarker, it has been associated
with insulin resistance, diabetes and cardiovascular diseases [16,17]. Telomeres are complex DNA–protein structures
located at the end of eukaryotic chromosomes which shorten with age in all replicating somatic cells [18] and are
associated with different pathological conditions [16,19]. In fact, functional telomeres play a key role in the protection
of chromosomes against genome instability [20]. Given that iron might promote oxidative stress [21], which could also
be a cause of shorter ATL [22], some studies evaluated the association between ATL and markers of iron metabolism.
In fact, in a study of 1174 healthy adults, Tf saturation (TfSat), was associated with shorter ATL [23].
The present study aims to evaluate the relationship betweeniron levelsand ATL in male adults diagnosed with HH.
Materials and methods
Subjects and study protocol
Thirty-eight patients with either TfSat > 50% or ferritin concentration > 300 ng/ml were recruited from the Hepa-
tology Division of the University Hospital ‘José de San Mart́ın’ between 2010 and 2012. HH was diagnosed by liver
histology compatible with primary IO (iron deposition preferentially within hepatocytes in the periportal region
of the hepatic lobule). Among the 38 patients recruited, 13 did not present liver histology compatible with IO and
were excluded from the study. Additional inclusion criteria were adult age and male sex. Exclusion criteria were: dia-
betes, hypothyroidism, cirrhosis, viral hepatitis, HIV infection or cancer. Among the 25 patients with HH included,
8 showed overt IO (TfSat > 50% and ferritin concentration > 300 ng/ml) at the time of the analysis (HH with IO)
and the remaining 17 presented TfSat > 50% but ferritin concentration < 300 ng/ml (HH w/o IO). These 17 patients
had previously presented IO and had been submitted to a successful phlebotomy to decrease body iron levels. Eight
patients were homozygous for the C282Y polymorphism, two were heterozygous for C282Y, one was homozygous
for H63D, seven were heterozygous for H63D, one was a compound heterozygote for C282Y/H63D and six were
wildtype. Twenty-five age-matched male healthy subjects without clinical or biochemical signs of IO and wildtype
for mutations in the HFE gene were also included. A single blood sample from each subject was drawn from the ante-
cubital vein after a 12-h overnight fast. Whole blood was used to determine the complete blood count and an aliquot
was stored at −20◦C to perform the ATL tests. Serum samples were immediately employed for general biochemical
determinations.
The present study was carried out in accordance with the Declaration of Helsinki and its later amendments or
comparable ethical standards. The protocol was approved by the Ethical Committees from University Hospital ‘José
de San Mart́ın’ and from the School of Pharmacy and Biochemistry, University of Buenos Aires. All patients signed
an informed consent to participate in the study.
Anthropometric, analytical and genetic procedures
Height and weight were measured with the subject wearing light clothes and without shoes. Body mass index (BMI)
was calculated and BMI categories were defined according to the World Health Organization (WHO) adult def-
inition [24]. Complete blood count was carried out in a LH750 autoanalyzer (Beckman Coulter, Fullerton, CA,
U.S.A.). Plasma Tf, apolipoprotein (apo) A-I and apo B concentrations were measured by nephelometry (IMMAGE®,
Beckman Coulter, Fullerton, CA, U.S.A.). Ferritin concentration was assayed by an electrochemiluminescence assay
(VITROS® ECiQ, Ortho-Clinical Diagnostics, Raritan City, NJ, U.S.A.). Serum levels of iron, glucose, triglycerides
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Table 1 Clinical and metabolic characteristics from IO patients and control subjects
Parameter HH with IO (n=8) HH w/o IO (n=17) Controls (n=25)
Age (y)* 61 (55–67)1 44 (34–55)2 49 (35–57)2
BMI (kg/m2)* 28 +− 31 28 +− 21 24 +− 22
Glucose (mg/dl)* 102 (95–114)1 95 (90–113)1 89 (86–95)2
TG (mg/dl) 96 (80–133) 113 (77–158) 86 (65–114)
TC (mg/dl) 167 +− 32 178 +− 38 186 +− 30
LDL-C (mg/dl) 99 +− 20 112 +− 35 119 +− 28
HDL-C (mg/dl) 50 +− 13 44 +− 8 48 +− 11
Apo A–I (mg/dl) 135 +− 30 127 +− 13 138 +− 31
Apo B (mg/dl) 84 +− 20 80 +− 32 94 +− 19
AST (IU/l)* 48 (32–57)1 32 (22–45)2 19 (18–26)2
ALT (IU/l)* 52 (28–72)1 28 (21–34)2 20 (17–23)2
Albumin (g/dl) 4.3 +− 0.3 4.4 +− 0.3 4.3 +− 0.1
Hepcidin/ferrtin ratio* 0.03 +− 0.021 0.22 +− 0.212 0.23 +− 0.172
Tf (mg/dl)* 203 +− 381 248 +− 302 249 +− 332
Abbreviations: TC, total cholesterol; TG, triglyceride.
* = P<0.01. Different superscript numbers over the mean or the median indicate significantly dissimilar groups.
and total cholesterol as well as the activities of hepatic enzymes were quantified by standardized methods (Roche Di-
agnostics, Mannheim, Germany) in a COBAS C501 autoanalyzer (Roche Diagnostics, Mannheim, Germany). LDL-C
and HDL-C concentrations were determined by selective precipitation methods.
Measurement of ATL
The ATL measurement was carried out by qPCR as previously described [25], in aStepOne ™ Real-Time PCR System
(Applied Biosystems). Genomic DNA was extracted from peripheral blood leukocytes by standard protocols [26].
For each DNA sample, two consecutive reactions were performed: the first one to amplify a fragment of 75 bp of
the single copy gene RPLPO (ribosomal protein, large, PO), and the second one for the telomeric sequence. They
both were used for standard curve constructions, and allowed the genome/reaction number (S) and the of telomeric
sequence/reaction (T) values to be exported from the respective standard curve. The calculation of the T/S ratio
resulted in the kbp of telomeric sequence per cell for each individual determination.
Statistical analyses
The Shapiro–Wilks method was employed to assess data distribution. Normally distributed variables were expressed
as mean +− SD and skewed-distributed variables as median (interquartile range [IQR]). Differences were analyzed
by ANOVA employing Tukey’s post-hoc test; or by Kruskal–Wallis and paired comparison post-hoc test according
to normal or skewed data distribution, respectively. Significance was defined as P<0.05 in the two-tailed tests. For
all statistical analyses, the software INFOSTAT (GrupoInfostat, Universidad Nacional de Córdoba, Argentina) was
employed.
Results
Clinical and metabolic characteristics
HH patients with overt IO were older (P<0.001) and, therefore, statistical analysis was carried out adjusting by age.
Furthermore, HH patients with IO also showed higher AST and ALT activities, as well as ferritin concentration than
HH patients without IO or control subjects (P<0.001) (Table 1). In turn, all these parameters were similar in HH
patients without IO and controls. Patients with HH, disregarding the iron status, showed higher BMI and glucose
levels than the controls (both P<0.01). Finally, TfSat was significantly different in the three groups studied finding
the highest values in HH patients with IO and the lowest ones in control subjects (Figure 1). Lipid and lipoprotein
profile were similar in all the groups.
Iron metabolism parameters
HH patient with IO showed higher levels of ferritin, TfSat (%), and body iron plus lower Tf compared with both
HH patients without IO and controls. Additionally, HH patients without IO presented higher TfSat (%) and body
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Figure 1. Iron metabolism in IO patients and control subjects
Panel A: Ferritin; Panel B: Transferrin Saturation (Transf. Sat.); Panel C: Body Iron; Panel D: Hepcidin. Different letters (a–c) indicate
statistically significant differences.
iron than control subjects. There were no differences among the groups in hepcidin concentration (Figure 1), but
hepcidin/ferritin ratio was significantly lower in HH patients with IO (Table 1).
ATL in patients with HH
A linear trend between the groups (P for trend<0.01) was observed. ATL were shorter in patients with overt IO
than in controls (Figure 2). Differences in ATL remained statistically significant in a model adjusted by age, BMI and
glucose levels (P<0.05).
ATL was significantly correlated with BMI (r = −0.37; P<0.05), glucose (r = −0.26; P<0.01), AST (r = −0.36;
P<0.05), ALT (r =−0.35, P<0.05), TfSat (r =−0.26; P<0.05), ferritin (r =−0.38; P<0.01), and hepcidin (r =−0.28;
P<0.05). Moreover, no association was detected between HFE genotype/allele distribution and ATL. In multivariate
analysis, glucose levels remained the only significant predictor of ATL (r2 = 0.32; β = −0.51; P<0.01) in a model
that also included age, BMI and ferritin.
Discussion
Telomere shortening can impact tissue homeostasis by impairing cell proliferation and giving rise to genome insta-
bility, thus constituting the bases for the development of different pathological conditions [27]. The present study
shows that HH patients with overt IO featured significantly shorter ATL while HH patients without IO showed only
mild alterations in comparison with healthy controls. The exposition to elevated iron levels over time might be an
important factor leading to telomere attrition in HH. The present results highlight the importance of early diagnosis
and treatment of IO to preserve ATL.
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Figure 2. Leukocyte telomere length in healthy controls and IO patients
Different letters (a-b) indicate statistically significant differences. *P<0.01.
Excess iron deposition has been shown to be associated with oxidative damage of both circulating biomolecules and
cells in a process that accelerates the physiologic changes that naturally occur with aging and leads, among others, to
age-related conditions [3–7]. In fact, excess iron accumulation displays multiple toxic effects, which are mostly based
on its ability to catalyze the generation of free radicals, resulting in cell death and tissue injury [21]. ROS generation
is responsible for the onset of different cellular stress responses such as DNA damage, organelle fragmentation and
membrane blebbing. Apart from being directly cytotoxic, iron and free radicals activate inflammatory cells, increasing
cytokine production and further generation of ROS [28]. Evidence suggests that free radicals may damage telomere
DNA and enhance its shortening [22]. Hence, ATL has been proposed as a marker of cumulative oxidative stress and
biological aging [18,22,29].
Apart from the differences observed in the present study in telomere length among the three studied groups, the
process of shortening seemed to be associated with the presence of IO. This finding is in agreement with a previous
report [30] which showed that iron phenotype and not HFE genotype had a significant effect on telomere length.
Patients with IO and, consequently, with the highest values of TfSat and ferritin, showed the shortest telomeres. Fur-
thermore, our study indicates a significant inverse association between TfSat and ferritin levels with telomere length.
Similar findings have also been previously reported by Mainou et al. [31], they observed that individuals with high
TfSat presented shortened telomere length when compared with those with low TfSat. However, it is important to
note that the present study did not include healthy controls and TfSat was the only parameter associated with iron
metabolism analyzed in the study. Regarding ferritin levels, Liu et al. [32] observed that telomere length was negatively
associated with the presence of high ferritin levels. Nevertheless, in the present study the association between ferritin
and ATL was only significant for individuals over 65 years old. Notably, in the present study, ATL was negatively
associated with markers of liver damage AST and ALT. This is interesting because the liver is one of the main targets
of free radical-induced damage in IO patients [21]. Moreover, in the present study, ATL was inversely correlated with
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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BMI. This finding is consistent with several prior studies carried out by our group which showed increases in BMI
and the presence of obesity as major determinants of telomere shortening [33,34].
In addition to oxidative stress, another trait of HH that would contribute to telomere shortening, is inflammation
[35,36]. IO promotes liver inflammation which, in tandem with oxidative stress, could contribute to telomere attrition.
In particular, iron deposits could directly alter the phenotype of T cells present in the liver leading to changes in
cytokine expression [37]. In this regard, it is noteworthy that, as previously mentioned, ATL was negatively associated
with ALT and AST levels. Both ALT and AST are considered markers of liver inflammation [38] and would suggest
a link between the later and telomere shortening in IO patients.
Remarkably, in the multivariate analysis, glucose levels were the only independent predictor of ATL. This is an
interesting finding because it raises the possibility that telomere shortening in IO patients could be the result of al-
terations in carbohydrate metabolism commonly observed in these patients. Telomere shortening is known to be a
feature of diseases that primarily result from alterations in glucose homeostasis such as insulin resistance and dia-
betes [17]. Nevertheless, to our knowledge, this would be the first study to suggest that impairment in carbohydrate
metabolism could be the main factor responsible for telomere shortening in pathologies with high glucose as a sec-
ondary trait as is the case with IO. Thus, on these bases, patients with chronic conditions that are frequently associated
with hyperglycemia would be also prone to undergo a process of telomere shortening.
As far as we know, our study is the first to show that IO patients who underwent successful treatment aimed to re-
duce body iron levels and, therefore, systemic oxidative stress [39,40], present ATL values statistically similar to those
of healthy controls. This is consistent with previous findings, both in vivo and in vitro, that indicate a positive effect of
antioxidant therapy on telomere length [41,42]. Previous studies showed that the addition of N-acetylcysteine to both
human lymphocytes exposed to irradiation and human astrocytoma cells infected with the human immunodeficiency
virus decreases the rate of telomere attrition [43,44]. Similarly, serum drawn from subjects under a low-saturated fat
diet showed the slowest rate of telomere shortening when added to the culture medium of human umbilical vein
endothelial cells [45]. Furthermore, several studies reported an increase in telomere length after antioxidant sup-
plementation in animal models [46,47]. Moreover, different double-blind, randomized placebo-controlled studies
suggested that supplementation with ω-3 fatty acids could slow telomere attrition in both overweight patients and
older-age individuals [48,49]. Similarly, Zhu et al. [50] observed a significant decrease in telomere attrition in over-
weight individuals after 4 months of vitamin D supplementation.
The fact that iron depletion could decrease telomere attrition is noteworthy given that the latter has been associated
with shorter lifespan as well as a wide variety of age-related diseases and conditions, including cardiovascular disease,
diabetes, insulin resistance and hypertension [30,51–54]. Regarding cardiovascular disease, telomere length has been
proposed as a predictor of coronary heart disease events [55,56] and cardiovascular disease-related mortality [57,58].
In fact, telomere length would be associated with subclinical atherosclerosis markers such as carotid artery intima
media thickness [59,60] and carotid artery calcification [51,61].
In summary, we observed an association between ATL and IO overt condition. HH patients with overt IO featured
significantly shorter ATL, while HH patients without IO showed similar ATL when compared with healthy controls.
Conclusion
In conclusion, overt IO was associated with shorter ATL in patients with HH. Screening for IO is encouraged to
prevent iron-associated cellular damage and early telomere attrition. ATL could provide prognostic information for
IO-related complications in patients with HH.
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